Nashville, Tennessee (October 14, 2019) – Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and...
Findings of a recently published two-part study demonstrate that InterACT Rx™ can significantly enhance diagnosis and treatment of DDIs, improving...
Studies show an alarming prevalence of concurrent ingestion of interacting substances by patients and that providing physicians with clear, objective...
Employing a definitive test to detect substances whose interactions may cause adverse drug events can enhance a provider’s insights, drive clinical...
InterACT Rx™ identified at least one drug-drug interaction (DDI) between recently ingested substances in as many as 20% of patients. Nashville,...
AcuRiseID™ is a new urinalysis that monitors medication adherence in people with mental illness and substance abuse disorder Nashville, Tennessee (Sept....
Sign up for the Aegis Newsletter